168 related articles for article (PubMed ID: 34250410)
21. Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C; Fassunke J; Ernst A; Schömig-Markiefka B; Merkelbach-Bruse S; Bartenhagen C; Cartolano M; Ackermann S; Theissen J; Blattner-Johnson M; Jones B; Schramm K; Altmüller J; Nürnberg P; Ortmann M; Berthold F; Peifer M; Büttner R; Westermann F; Schulte JH; Simon T; Hero B; Fischer M
Br J Cancer; 2023 Apr; 128(8):1559-1571. PubMed ID: 36807339
[TBL] [Abstract][Full Text] [Related]
22. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
[TBL] [Abstract][Full Text] [Related]
23. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
24. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
25. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
26. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
[TBL] [Abstract][Full Text] [Related]
27. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
28. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
He MY; Li WK; Zheng QC; Zhang HX
ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
[TBL] [Abstract][Full Text] [Related]
29. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
30. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
[TBL] [Abstract][Full Text] [Related]
31. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
32. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
33. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
Kim EK; Kim S
Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
[TBL] [Abstract][Full Text] [Related]
34. Generation of induced pluripotent stem cell lines from two Neuroblastoma patients carrying a germline ALK R1275Q mutation.
Marin Navarro A; Day K; Kogner P; Wilhelm M; Falk A
Stem Cell Res; 2019 Jan; 34():101356. PubMed ID: 30605844
[TBL] [Abstract][Full Text] [Related]
35. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
36. Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.
Mazot P; Cazes A; Dingli F; Degoutin J; Irinopoulou T; Boutterin MC; Lombard B; Loew D; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
PLoS One; 2012; 7(3):e33581. PubMed ID: 22479414
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
38. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
[TBL] [Abstract][Full Text] [Related]
39. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.
Mazot P; Cazes A; Boutterin MC; Figueiredo A; Raynal V; Combaret V; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
Oncogene; 2011 Apr; 30(17):2017-25. PubMed ID: 21242967
[TBL] [Abstract][Full Text] [Related]
40. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.
Jamin Y; Glass L; Hallsworth A; George R; Koh DM; Pearson AD; Chesler L; Robinson SP
PLoS One; 2014; 9(3):e92886. PubMed ID: 24667968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
